settle an investment dispute with CellPro Inc.

CellPro Inc. said yesterday it settled a dispute with Corange over a December 1993 pact in which Corange was to buy a 15 percent stake in CellPro for $110 million.

Under that pact, Corange also had said it would pay an additional $110 million in other payments and fees to CellPro.

Yesterday, CellPro said Corange agreed to pay $30 million in exchange for certain supply rights and 1 million newly issued CellPro common shares.

Following the settlement, Corange will hold a total of 2.2 million CellPro shares, or about 15.4 percent of its stock.

Corange, the parent company of Boehringer Mannheim Pharmaceuticals Corp., will have paid a total of about $90 million in the deal.

The companies' collaboration called for Corange to buy the stake in CellPro by paying $50 million upfront, and making a $60 million installment 15 months later.